To provide cyclosporine analogues that posse enhanced efficacy and reduced toxicity compared with presently known cyclosporine.
There are provided cis and trans-isomers of cyclosporine A analogs referred to as ISATX247, and derivatives thereof. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The stereoselective synthetic pathways utilize a Witting reaction or organometallic reagents including inorganic elements, such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 wt.% of the (E)-isomer to about 90 to 10 wt.% of the (Z)-isomer, based on the total weight of the mixture.
YATSCOFF RANDALL W
FOSTER ROBERT T
JP2005511538A | 2005-04-28 | |||
JP2009197036A | 2009-09-03 | |||
JP5272140B2 | 2013-08-28 |
WO1999018120A1 | 1999-04-15 |
JPN6008063756; The Journal of Heart and Lung Transplantation Vol.20, No.2, 200102, page 161
JPN6008063757; モリソンボイド 有機化学(上)第6版 , 1994, 第186-188,362-366頁
JPN5004001601; ASPESLET L: TRANSPLANTATION PROCEEDINGS V33, 200102, P1048-1051
JPN6008063756; The Journal of Heart and Lung Transplantation Vol.20, No.2, 200102, page 161